{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:02:17Z","timestamp":1782932537979,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with hyperuricemia and gout are at an increased risk for cardiovascular (CV) disease. Inhibition of the xanthine oxidase with allopurinol or febuxostat have become the mainstay for urate lowering therapy. However, it has been suggested that febuxostat increases the risk for CV mortality as compared to allopurinol. The aim of this retrospective cohort study was to assess the CV risk among patients with febuxostat or allopurinol therapy. Patients who initiated urate lowering therapy with febuxostat or allopurinol between 2014 and 2017 were selected from the drug reimbursement database of the Austrian health insurances funds. The primary CV endpoint was a composite of angina pectoris, nonfatal myocardial infarction, nonfatal subarachnoid or cerebral hemorrhage, nonfatal ischemic stroke, or death from any cause. In total, 28.068 patients (62.1% male) with a mean age of 71\u00a0years were included. 7.767 initiated febuxostat treatment and 20.301 received allopurinol. The incidence rate per 100 patient-years of the composite primary endpoint was 448 (febuxostat) and 356 (allopurinol) with a corresponding adjusted hazard ratio (HR) of 0.58 (95% CI 0.53\u20130.63) for allopurinol vs. febuxostat initiators. Similar HR were found for secondary endpoints including all-cause mortality [0.61 (95% CI 0.55\u20130.68)] and separate analyses of cardiac events [0.48 (95% CI 0.38\u20130.61)] and ischemic stroke [0.47 (95% CI 0.36\u20130.61)]. Data from this Austrian population-based study suggests that febuxostat initiators are at an increased risk for nonfatal CV events or death from any cause as compared to those with allopurinol. This is consistent with CV concerns of other trials, which limited the broad therapeutic use of febuxostat.\n<\/jats:p>","DOI":"10.1007\/s00296-022-05139-8","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T11:29:34Z","timestamp":1653046174000},"page":"1597-1603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014\u20132017"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5853-9656","authenticated-orcid":false,"given":"Stefan","family":"Weisshaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Litschauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasa","family":"Sibinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kossmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wolzt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"5139_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/rheumatology\/key002","volume":"58","author":"T Pascart","year":"2019","unstructured":"Pascart T, Liote F (2019) Gout: state of the art after a decade of developments. Rheumatology (Oxford) 58:27\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/key002","journal-title":"Rheumatology (Oxford)"},{"key":"5139_CR2","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-217050","volume":"79","author":"Z Jin","year":"2020","unstructured":"Jin Z, Wang D, Zhang H, Liang J, Feng X, Zhao J, Sun L (2020) Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. Ann Rheum Dis 79:1014\u20131022. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217050","journal-title":"Ann Rheum Dis"},{"key":"5139_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK (2019) Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007\u20132016. Arthritis Rheumatol 71:991\u2013999. https:\/\/doi.org\/10.1002\/art.40807","journal-title":"Arthritis Rheumatol"},{"key":"5139_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.rdc.2014.01.001","volume":"40","author":"E Roddy","year":"2014","unstructured":"Roddy E, Choi HK (2014) Epidemiology of gout. Rheum Dis Clin North Am 40:155\u2013175. https:\/\/doi.org\/10.1016\/j.rdc.2014.01.001","journal-title":"Rheum Dis Clin North Am"},{"key":"5139_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00296-021-04876-6","volume":"41","author":"P Cox","year":"2021","unstructured":"Cox P, Gupta S, Zhao SS, Hughes DM (2021) The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. Rheumatol Int 41:1209\u20131219. https:\/\/doi.org\/10.1007\/s00296-021-04876-6","journal-title":"Rheumatol Int"},{"key":"5139_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","volume":"10","author":"P Richette","year":"2014","unstructured":"Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T (2014) Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol 10:654\u2013661. https:\/\/doi.org\/10.1038\/nrrheum.2014.124","journal-title":"Nat Rev Rheumatol"},{"key":"5139_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T (2020) 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Rheumatol 72:879\u2013895. https:\/\/doi.org\/10.1002\/acr.24180","journal-title":"Arthritis Rheumatol"},{"key":"5139_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Nivorozhkin A, Szabo C (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87\u2013114. https:\/\/doi.org\/10.1124\/pr.58.1.6","journal-title":"Pharmacol Rev"},{"key":"5139_CR9","doi-asserted-by":"publisher","first-page":"ii15","DOI":"10.1093\/rheumatology\/kep088","volume":"48","author":"NL Edwards","year":"2009","unstructured":"Edwards NL (2009) Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford) 48:ii15\u2013ii19. https:\/\/doi.org\/10.1093\/rheumatology\/kep088","journal-title":"Rheumatology (Oxford)"},{"key":"5139_CR10","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450\u20132461. https:\/\/doi.org\/10.1056\/NEJMoa050373","journal-title":"N Engl J Med"},{"key":"5139_CR11","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:1540\u20131548. https:\/\/doi.org\/10.1002\/art.24209","journal-title":"Arthritis Rheum"},{"key":"5139_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C (2009) Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 48:188\u2013194. https:\/\/doi.org\/10.1093\/rheumatology\/ken457","journal-title":"Rheumatology (Oxford)"},{"key":"5139_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, Investigators C (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200\u20131210. https:\/\/doi.org\/10.1056\/NEJMoa1710895","journal-title":"N Engl J Med"},{"key":"5139_CR14","unstructured":"FDA (2019). FDA adds boxed warning for increased risk of death with gout medicine uloric (febuxostat). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat. Accessed 28 Mar 2022"},{"key":"5139_CR15","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/rheumatology\/kez189","volume":"58","author":"EH Kang","year":"2019","unstructured":"Kang EH, Choi HK, Shin A, Lee YJ, Lee EB, Song YW, Kim SC (2019) Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology (Oxford) 58:2122\u20132129. https:\/\/doi.org\/10.1093\/rheumatology\/kez189","journal-title":"Rheumatology (Oxford)"},{"key":"5139_CR16","doi-asserted-by":"publisher","first-page":"653e657","DOI":"10.1016\/j.amjmed.2015.01.013","volume":"128","author":"SC Kim","year":"2015","unstructured":"Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH (2015) Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med 128:653e657\u2013653e616. https:\/\/doi.org\/10.1016\/j.amjmed.2015.01.013","journal-title":"Am J Med"},{"key":"5139_CR17","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/art.40583","volume":"70","author":"H Choi","year":"2018","unstructured":"Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R (2018) New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated food and drug administration public safety alert. Arthritis Rheumatol 70:1702\u20131709. https:\/\/doi.org\/10.1002\/art.40583","journal-title":"Arthritis Rheumatol"},{"key":"5139_CR18","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","volume":"138","author":"M Zhang","year":"2018","unstructured":"Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, Kim SC (2018) Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study. Circulation 138:1116\u20131126. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033992","journal-title":"Circulation"},{"key":"5139_CR19","unstructured":"PHARMIG (2020). Daten & Fakten 2020 Arzneimittel und Gesundheitswesen in \u00d6sterreich. https:\/\/www.pharmig.at\/media\/2890\/daten_und_fakten_2020_deutsch.pdf. Accessed 28 Mar 2022"},{"key":"5139_CR20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrcardio.2009.163","volume":"6","author":"AM Clark","year":"2009","unstructured":"Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A (2009) Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol 6:712\u2013722. https:\/\/doi.org\/10.1038\/nrcardio.2009.163","journal-title":"Nat Rev Cardiol"},{"key":"5139_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","volume":"325","author":"K Yadav","year":"2021","unstructured":"Yadav K, Lewis RJ (2021) Immortal time bias in observational studies. JAMA 325:686\u2013687. https:\/\/doi.org\/10.1001\/jama.2020.9151","journal-title":"JAMA"},{"key":"5139_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","volume":"41","author":"RJ Johnson","year":"2003","unstructured":"Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41:1183\u20131190. https:\/\/doi.org\/10.1161\/01.HYP.0000069700.62727.C5","journal-title":"Hypertension"},{"key":"5139_CR23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1053\/j.ajkd.2006.08.019","volume":"48","author":"ME Suliman","year":"2006","unstructured":"Suliman ME, Johnson RJ, Garcia-Lopez E, Qureshi AR, Molinaei H, Carrero JJ, Heimburger O, Barany P, Axelsson J, Lindholm B, Stenvinkel P (2006) J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 48:761\u2013771. https:\/\/doi.org\/10.1053\/j.ajkd.2006.08.019","journal-title":"Am J Kidney Dis"},{"key":"5139_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.ajkd.2014.04.024","volume":"64","author":"MC Odden","year":"2014","unstructured":"Odden MC, Amadu AR, Smit E, Lo L, Peralta CA (2014) Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988\u20131994 and 1999\u20132002. Am J Kidney Dis 64:550\u2013557. https:\/\/doi.org\/10.1053\/j.ajkd.2014.04.024","journal-title":"Am J Kidney Dis"},{"key":"5139_CR25","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/acr.22067","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Schmidt BM, Franklin JM, Liu J, Solomon DH, Schneeweiss S (2013) Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken) 65:2008\u20132014. https:\/\/doi.org\/10.1002\/acr.22067","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5139_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC (2015) Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 11:437\u2013441. https:\/\/doi.org\/10.1038\/nrrheum.2015.30","journal-title":"Nat Rev Rheumatol"},{"key":"5139_CR27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1144","volume":"9","author":"Z Varga","year":"2017","unstructured":"Varga Z, Sabzwari SRA, Vargova V (2017) Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus 9:e1144. https:\/\/doi.org\/10.7759\/cureus.1144","journal-title":"Cureus"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05139-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05139-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05139-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T04:03:59Z","timestamp":1659499439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05139-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5139"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05139-8","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"11 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Since only anonymized data were used, informed consent by the insured individuals was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}